The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Prospective study on the relationship between infections and multiple sclerosis exacerbations
Open accessAbstract
One of the characteristics of multiple sclerosis is the unpredictable occurrence of exacerbations and remissions. These fluctuations in disease activity are related to alterations in (auto-)immune activity. Exacerbations lead to short-term morbidity, but may also influence long-term disability. This longitudinal study in 73 patients with relapsing-remitting multiple sclerosis assessed the contribution of systemic infections to the natural course of exacerbations. In addition, we analysed whether infections lead to an increase in the number of gadolinium-enhancing lesions. A total of 167 infections and 145 exacerbations were observed during 6466 patient weeks. During a predefined at-risk period (ARP) of 2 weeks before until 5 weeks after the onset of a clinical infection (predominantly upper airway infections), there was an increased risk of exacerbations (rate ratio 2.1), which is in accordance with previous studies. Exacerbations with onset during the ARP led more frequently to sustained deficit [increase of > or =1 Expanded Disability Status Scale (EDSS) point or > or =0.5 above EDSS 5.5 for >3 months] than exacerbations with onset outside the ARP, with a rate ratio of 3.8. Minor and major exacerbations were equally distributed between the ARP and non-ARP onset groups. ARP exacerbations were associated with significantly higher plasma levels of the inflammatory marker soluble intracellular adhesion molecule 1 than non-ARP exacerbations, indicating relatively enhanced immune activation during ARP relapses. Three serial MRI scans were performed after the onset of an infection over a 6-week period. There was no difference in the number of gadolinium-enhancing lesions between the three time points. In conclusion, exacerbations in the context of a systemic infection lead to more sustained damage than other exacerbations. There is no indication that this effect occurs through enhanced opening of the blood-brain barrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) · Neurology · doi:10.1212/wnl.45.7.1277 · Cited by 916
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
von Büdingen, H.-C., Palanichamy, A., Lehmann-Horn, K., Michel, B. A., & Zamvil, S. S. (2015) · European Neurology · doi:10.1159/000377675 · Cited by 1,463
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172
“…sclerosis Systemic inflammation exacerbates CNS disease in relapsingremitting MS (RRMS), and these exacerbations have been shown tooccur in the absence or presence of disruptiveBBBchanges inboth EAE (Moreno et al., 2011; Serres et al., 2009) andMS (Buljevac et al., 2002; Correale et al., 2006).”
Microglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Lymphoid neogenesis in chronic inflammatory diseases
Aloisi, F., & Pujol-Borrell, R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1786 · Cited by 908
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Huang, X., Hussain, B., & Chang, J. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13569 · Cited by 709
A functional and structural basis for TCR cross-reactivity in multiple sclerosis
Lang, H. L. E., Jacobsen, H., Ikemizu, S., Andersson, C., Harlos, K., Madsen, L., Hjorth, P., Sondergaard, L., Svejgaard, A., Wucherpfennig, K., et al. (2002) · Nature Immunology · doi:10.1038/ni835 · Cited by 591
Perry, V. H., & Teeling, J. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0382-8 · Cited by 590
TLR-dependent T cell activation in autoimmunity
Mills, K. H. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3095 · Cited by 443
The impact of systemic infection on the progression of neurodegenerative disease
Perry, V. H., Newman, T. A., & Cunningham, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1032 · Cited by 428
Sexual function problems and help seeking behaviour in Britain: national probability sample survey
Mercer, C. H., Fenton, K. A., Johnson, A. M., Wellings, K., Macdowall, W., McManus, S., Nanchahal, K., & Erens, B. (2003) · BMJ · doi:10.1136/bmj.327.7412.426 · Cited by 380
Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis
Prinz, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26078 · Cited by 380
Toll‐like receptors in central nervous system glial inflammation and homeostasis
Kielian, T. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20767 · Cited by 361
Bielekova, B., Richert, N., Howard, T., Blevins, G., Markovic-Plese, S., McCartin, J., Würfel, J., Ohayon, J., Waldmann, T. A., McFarland, H. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402653101 · Cited by 315
A UK consensus on the management of the bladder in multiple sclerosis
Fowler, C. J., Panicker, J. N., Drake, M., Harris, C., Harrison, S. C. W., Kirby, M., Lucas, M., Macleod, N., Mangnall, J., North, A., et al. (2009) · Postgraduate Medical Journal · doi:10.1136/jnnp.2008.159178 · Cited by 308
Infectious causes of multiple sclerosis
Giovannoni, G., Cutter, G. R., Lunemann, J., Martin, R., Münz, C., Sriram, S., Steiner, I., Hammerschlag, M. R., & Gaydos, C. A. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70577-4 · Cited by 295
The initiation and prevention of multiple sclerosis
Ascherio, A., Munger, K. L., & Lünemann, J. D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.198 · Cited by 289
Contribution of systemic inflammation to chronic neurodegeneration
Perry, V. H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0722-x · Cited by 277
Smouldering multiple sclerosis: the ‘real MS’
Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobaeus, E., Jensen, M. B., García-Domínguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., et al. (2022) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211066751 · Cited by 271
The risk of relapses in multiple sclerosis during systemic infections
Correale, J., Fiol, M., & Gilmore, W. (2006) · Neurology · doi:10.1212/01.wnl.0000233834.09743.3b · Cited by 256
Immunopathogenesis and immunotherapy of multiple sclerosis
Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., & Hartung, H.-P. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0154 · Cited by 254
Teeling, J. L., & Perry, V. H. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.031 · Cited by 252
Hou, W., Kang, H. S., & Kim, B. S. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082030 · Cited by 246
Zhou, H., Andonegui, G., Wong, C. H. Y., & Kubes, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901309 · Cited by 174
Systemic Inflammation Modulates Fc Receptor Expression on Microglia during Chronic Neurodegeneration
Lunnon, K., Teeling, J. L., Tutt, A. L., Cragg, M. S., Glennie, M. J., & Perry, V. H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903833 · Cited by 138
The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes
Sellner, J., Hemmer, B., & Mühlau, M. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.013 · Cited by 142
Tallantyre, E. C., Causon, E. G., Harding, K. E., Pickersgill, T. P., & Robertson, N. P. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514538333 · Cited by 18
Metadata
- Authors
- Buljevac, D., Flach, H. Z., Hop, W. C. J., Hijdra, D., Laman, J. D., Savelkoul, H. F. J., van der Meché, F. G. A., van Doorn, P. A., & Hintzen, R. Q.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-05
- Volume
- 125
- Issue
- 5
- Pages
- 952-960
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2118966296
- Cited by
- 427
- References
- 40
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.